US FDA’s Stance On CBD In Cosmetics Hasn’t Changed, And Neither Have Marketing Challenges
The FDA continues working to close cannabidiol data gaps while maintaining that CBD-containing cosmetics cannot be adulterated, misbranded or marketed as affecting body structure/function or treating or preventing disease, including skin ailments. Cosmetics office head Linda Katz revisited the issue during the Independent Beauty Association’s annual FDA Cosmetics Regulations Workshop.
You may also be interested in...
Office of Cosmetics and Colors Linda Katz emphasizes FDA sees allergen labeling as a public health issue. While many allergic reactions are minor, “consumers who are extremely or exclusively sensitive to a particular ingredient should have a right to know.”
US FDA’s Cosmetics Director Katz Cites Fragrance Allergens, Talc-Containing Products Among Priorities
Linda Katz, director of the US FDA’s Office of Cosmetics and Colors, offered insight into priority cosmetics issues at the Independent Beauty Association’s virtual FDA Cosmetic Regulations Workshop.
IBA’s name change refines its identity as the representative of the independent and entrepreneurial beauty industry, according to the trade organization’s announcement. The group’s FDA Cosmetics Regulation Workshop, held annually since 1983 in cooperation with the FDA, will be virtual in 2020.